GLP-1 30mg

GLP-1 is a designer single GLP-1 receptor agonist analogue formulated at 30mg for preclinical investigation of glucagon-like peptide-1 receptor pharmacology, insulin secretion dynamics, and metabolic pathway modulation. As a member of the incretin hormone research class, GLP-1 engages the GLP-1 receptor (GLP-1R) — a class B G protein-coupled receptor expressed on pancreatic beta cells, enteroendocrine cells, cardiac tissue, and hypothalamic appetite circuits — to stimulate glucose-dependent insulin release and suppress glucagon secretion.

The 30mg research concentration supports robust preclinical programs requiring extended supply for longitudinal metabolic studies, dose-range investigations, and multi-cohort experimental designs. GLP-1R agonists have been among the most intensively studied compound classes in modern metabolic research, with mechanistic interest spanning pancreatic biology, cardiovascular protection, central appetite regulation, and neurological pathway modulation.

Molecular Information

CAS Number	89750-14-1
Molecular Formula	C₁₄₉H₂₃₂N₄₀O₄₅
Molecular Weight	3297.7 g/mol
Class	Designer GLP-1 Receptor Agonist Analogue
Strength	30 mg
Primary Target	GLP-1 Receptor (GLP-1R) — Class B GPCR
Purity	≥98% (HPLC)
Appearance	White lyophilized powder
Storage Form	Lyophilized peptide
Storage Information	Store in a refrigerated environment free of exposure to sunlight, moisture, or excessive heat.

Mechanisms of Research Interest

GLP-1R agonism activates adenylyl cyclase via Gαs coupling, elevating intracellular cAMP and triggering PKA-mediated phosphorylation cascades in pancreatic beta cells. This drives glucose-dependent insulin secretion — a mechanism that is self-limiting at normal glucose concentrations, providing a favorable safety profile for research models. Simultaneous suppression of glucagon release from alpha cells reduces hepatic glucose output.

Central GLP-1R activation in the hypothalamic arcuate nucleus and brainstem nucleus tractus solitarius modulates appetite circuits, reducing food intake through both immediate satiety signaling and longer-term feeding behavior regulation. Gastric emptying delay — mediated through vagal afferent pathways — extends the post-prandial satiety window. Cardiovascular protective effects have been studied in myocardial ischemia-reperfusion models, with GLP-1R activation demonstrating anti-inflammatory activity in vascular endothelial and smooth muscle tissue.

Research Applications

GLP-1 30mg is used in metabolic syndrome research, type 2 diabetes pathway investigation, pancreatic beta-cell function and mass studies, appetite regulation and feeding behavior models, cardiovascular protection research, GLP-1R pharmacology and structure-activity studies, and longitudinal obesity research programs requiring sustained compound supply.

Quality Assurance & Supplier Commitment

We maintain longstanding relationships with leading peptide lyophilizers and raw material suppliers, selected through an exhaustive vetting process that evaluates manufacturing practices, analytical capabilities, and regulatory compliance. Our API sourcing protocol includes certificate of analysis review, third-party analytical testing, and periodic supplier audits to ensure consistent purity, potency, and sterility standards across all product lines.

Each batch undergoes meticulous quality control verification prior to release, including HPLC purity analysis, mass spectrometry confirmation, and endotoxin testing where applicable. Our commitment to sourcing integrity ensures researchers receive material of the highest available quality.